Cytrill is a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases. The funding will enable next steps for the clinical development of CIT-013, a first-in-class monoclonal antibody which targets Neutrophil Extracellular Traps (NETs), a fundamental component of the inflammatory process that has yet to be addressed therapeutically. NETs are web-like structures composed of DNA, histones, and antimicrobial proteins, released by neutrophils to trap and degrade pathogens. Excessive NET formation can contribute to tissue damage and chronic inflammation in various immune-mediated inflammatory disorders.
“It was a pleasure assisting this consortium of global life sciences investors in Citryll’s Series B funding round”, says Corporate M&A partner Ruud Smits. “Congratulations to Citryll on this milestone. We look forward to their progress in their transformative approach to treating inflammatory disorders.” The team further consisted of Hugo Blom, Emma Wiggers, Wijnand Bossenbroek, Daan Hagelstein, Eline Keuning, Jeroen Boelens, Laura Zanting, Lauren Delleman and Harm Ruiter.
Press release: